Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 235

1.

Plasma efavirenz concentrations and the association with CYP2B6-516G >T polymorphism in HIV-infected Thai children.

Puthanakit T, Tanpaiboon P, Aurpibul L, Cressey TR, Sirisanthana V.

Antivir Ther. 2009;14(3):315-20.

PMID:
19474465
2.

Correlation of CYP2B6-516G > T Polymorphism with Plasma Efavirenz Concentration and Depression in HIV-Infected Adults in Northern Thailand.

Aurpibul L, Chotirosniramit N, Sugandhavesa P, Kosashunhanan N, Thetket S, Supindham T, Piyamongkol W, Supparatpinyo K.

Curr HIV Res. 2012 Dec;10(8):653-60.

PMID:
22950382
3.

Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26.

Gatanaga H, Hayashida T, Tsuchiya K, Yoshino M, Kuwahara T, Tsukada H, Fujimoto K, Sato I, Ueda M, Horiba M, Hamaguchi M, Yamamoto M, Takata N, Kimura A, Koike T, Gejyo F, Matsushita S, Shirasaka T, Kimura S, Oka S.

Clin Infect Dis. 2007 Nov 1;45(9):1230-7. Epub 2007 Sep 24.

4.

Influence of CYP2B6 516G>T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of efavirenz in HIV-infected South African children.

Viljoen M, Karlsson MO, Meyers TM, Gous H, Dandara C, Rheeders M.

Eur J Clin Pharmacol. 2012 Apr;68(4):339-47. doi: 10.1007/s00228-011-1148-7. Epub 2011 Nov 6.

PMID:
22057858
5.

CYP2B6 (c.516G-->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients.

Kwara A, Lartey M, Sagoe KW, Rzek NL, Court MH.

Br J Clin Pharmacol. 2009 Apr;67(4):427-36. doi: 10.1111/j.1365-2125.2009.03368.x.

6.

Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults.

Sukasem C, Cressey TR, Prapaithong P, Tawon Y, Pasomsub E, Srichunrusami C, Jantararoungtong T, Lallement M, Chantratita W.

Br J Clin Pharmacol. 2012 Dec;74(6):1005-12. doi: 10.1111/j.1365-2125.2012.04288.x.

7.

Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients.

Wyen C, Hendra H, Vogel M, Hoffmann C, Knechten H, Brockmeyer NH, Bogner JR, Rockstroh J, Esser S, Jaeger H, Harrer T, Mauss S, van Lunzen J, Skoetz N, Jetter A, Groneuer C, Fätkenheuer G, Khoo SH, Egan D, Back DJ, Owen A; German Competence Network for HIV/AIDS.

J Antimicrob Chemother. 2008 Apr;61(4):914-8. doi: 10.1093/jac/dkn029. Epub 2008 Feb 14.

8.

Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients.

Manosuthi W, Sukasem C, Lueangniyomkul A, Mankatitham W, Thongyen S, Nilkamhang S, Manosuthi S, Sungkanuparph S.

Antimicrob Agents Chemother. 2013 Feb;57(2):1019-24. doi: 10.1128/AAC.02023-12. Epub 2012 Dec 17.

9.

Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphism.

Saitoh A, Fletcher CV, Brundage R, Alvero C, Fenton T, Hsia K, Spector SA.

J Acquir Immune Defic Syndr. 2007 Jul 1;45(3):280-5.

PMID:
17356468
10.

Mid-dosing interval efavirenz plasma concentrations in HIV-1-infected children in Rwanda: treatment efficacy, tolerability, adherence, and the influence of CYP2B6 polymorphisms.

Mutwa PR, Fillekes Q, Malgaz M, Tuyishimire D, Kraats Rv, Boer KR, Burger DM, van Schaik RH, Muganga N, Geelen SP.

J Acquir Immune Defic Syndr. 2012 Aug 1;60(4):400-4. doi: 10.1097/QAI.0b013e3182569f57.

PMID:
22481606
11.

CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients.

Kwara A, Lartey M, Sagoe KW, Kenu E, Court MH.

AIDS. 2009 Oct 23;23(16):2101-6. doi: 10.1097/QAD.0b013e3283319908.

12.

Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients.

Elens L, Vandercam B, Yombi JC, Lison D, Wallemacq P, Haufroid V.

Pharmacogenomics. 2010 Sep;11(9):1223-34. doi: 10.2217/pgs.10.94.

PMID:
20860463
13.

CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patients.

Chen J, Sun J, Ma Q, Yao Y, Wang Z, Zhang L, Li L, Sun F, Lu H.

Ther Drug Monit. 2010 Oct;32(5):573-8. doi: 10.1097/FTD.0b013e3181ea953c.

PMID:
20625352
14.

Effect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV Infection.

Meng X, Yin K, Wang J, Dong P, Liu L, Shen Y, Shen L, Ma Q, Lu H, Cai W.

PLoS One. 2015 Jun 24;10(6):e0130583. doi: 10.1371/journal.pone.0130583. eCollection 2015.

15.

CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children.

Saitoh A, Sarles E, Capparelli E, Aweeka F, Kovacs A, Burchett SK, Wiznia A, Nachman S, Fenton T, Spector SA.

AIDS. 2007 Oct 18;21(16):2191-9.

PMID:
18090046
16.

A pharmacokinetic and pharmacogenetic study of efavirenz in children: dosing guidelines can result in subtherapeutic concentrations.

ter Heine R, Scherpbier HJ, Crommentuyn KM, Bekker V, Beijnen JH, Kuijpers TW, Huitema AD.

Antivir Ther. 2008;13(6):779-87.

PMID:
18839779
17.

Associations between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 alleles in relation to efavirenz and nevirapine pharmacokinetics in HIV-infected individuals.

Heil SG, van der Ende ME, Schenk PW, van der Heiden I, Lindemans J, Burger D, van Schaik RH.

Ther Drug Monit. 2012 Apr;34(2):153-9. doi: 10.1097/FTD.0b013e31824868f3.

PMID:
22354160
18.

Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens.

Tsuchiya K, Gatanaga H, Tachikawa N, Teruya K, Kikuchi Y, Yoshino M, Kuwahara T, Shirasaka T, Kimura S, Oka S.

Biochem Biophys Res Commun. 2004 Jul 9;319(4):1322-6.

PMID:
15194512
19.

Pharmacokinetics of plasma efavirenz and CYP2B6 polymorphism in southern Chinese.

To KW, Liu ST, Cheung SW, Chan DP, Chan RC, Lee SS.

Ther Drug Monit. 2009 Aug;31(4):527-30. doi: 10.1097/FTD.0b013e3181ad74a4.

PMID:
19531981
20.

High prevalence of the CYP2B6 516G-->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe.

Nyakutira C, Röshammar D, Chigutsa E, Chonzi P, Ashton M, Nhachi C, Masimirembwa C.

Eur J Clin Pharmacol. 2008 Apr;64(4):357-65. Epub 2007 Dec 5.

PMID:
18057928
Items per page

Supplemental Content

Write to the Help Desk